Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

By R. Capdeville, E. Buchdunger, J. Zimmermann, A. Matter. Nature reviews. Drug discovery, 2002

1,378 citations recorded by the source corpus.

Subfields: Gastroenterology, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/efef145d80f23a579e9d2500988e81611949528c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

Brent R. Stockwell

In Oncology

Citations in the corpus

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006, background): “However, before the approval of sorafenib, two first-generation targeted anticancer agents — imatinib (Gleevec; Novartis) and erlotinib (Tarceva; Genentech), which target Bcr–Abl and EGFR, respectively — had begun to show clinical benefi”
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004, background): “The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.”
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. (2003, background): “We postulated that these experimentally transformedcoprotein found in Philadelphia chromosome-positive chronic myelogenous leukemia (Capdeville et al., 2002), and Herceptin cells would permit us to identify genotype-selective agents from both known and novel compound sources that exhibit…”
How were new medicines discovered? (2011, background): “; and imatinib, which inhibits the BCR–ABL kinase by stabilizing its inactive conformatio”
The secret ally: immunostimulation by anticancer drugs (2012, background): “In 1960, Nowell and Hungerford5 first described the Philadelphia chromosome — t(9;22)(q34;q11) — an abnormality specifically associated with chronic myelogenous leukaemia (CML)6.”
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors (2007, methodology): “We apply the methodology to three drugs targeting the oncogenic BCR-ABL kinase, which induces chronic myelogenous leukemi”
Kinase-targeted cancer therapies: progress, challenges and future directions (2018, methodology): “Following the FDA approval of imatinib, different strategies have been used for the development of single and multi-target kinase inhibitors for cancer treatment [78].”
Awakening guardian angels: drugging the p53 pathway (2009, background): “gov/drugdictionary/?CdrID=37862">imatinib (also known as Glivec or Gleevec), which is effective against tumours harbouring translocations of ABL1 (Ref”
Molecular imaging in drug discovery and development (2003, neutral): “Examples of such therapies include inhibitors of specific kinases (for example, Glivec/Gleevec, which targets the BCR–ABL receptor tyrosine kinas”